Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.710
-0.060 (-3.39%)
At close: Nov 3, 2025, 4:00 PM EST
1.730
+0.020 (1.17%)
After-hours: Nov 3, 2025, 4:43 PM EST
Sunshine Biopharma Employees
Sunshine Biopharma had 52 employees as of December 31, 2024. The number of employees increased by 8 or 18.18% compared to the previous year.
Employees
52
Change (1Y)
8
Growth (1Y)
18.18%
Revenue / Employee
$698,880
Profits / Employee
-$121,281
Market Cap
7.79M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | 8 | 18.18% |
| Dec 31, 2023 | 44 | -2 | -4.35% |
| Dec 31, 2022 | 46 | 43 | 1,433.33% |
| Dec 31, 2021 | 3 | 0 | - |
| Dec 31, 2020 | 3 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SBFM News
- 6 days ago - Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM) - Accesswire
- 6 days ago - Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea - Accesswire
- 14 days ago - Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline - Accesswire
- 18 days ago - Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin - Accesswire
- 20 days ago - Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM) - Accesswire
- 20 days ago - Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM) - Accesswire
- 20 days ago - Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience - Accesswire
- 25 days ago - Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections - Accesswire